Calamos Advisors LLC Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Calamos Advisors LLC reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,211 shares of the biopharmaceutical company’s stock after selling 173 shares during the period. Calamos Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $11,603,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. FMR LLC lifted its position in shares of Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after buying an additional 669,517 shares in the last quarter. Northern Trust Corp raised its stake in Regeneron Pharmaceuticals by 3.3% during the 3rd quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock valued at $878,271,000 after purchasing an additional 34,326 shares during the period. Morgan Stanley raised its stake in Regeneron Pharmaceuticals by 2.7% during the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after purchasing an additional 25,792 shares during the period. Bank of New York Mellon Corp raised its stake in Regeneron Pharmaceuticals by 0.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 967,414 shares of the biopharmaceutical company’s stock valued at $796,142,000 after purchasing an additional 2,666 shares during the period. Finally, Norges Bank bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $697,296,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $896.82 on Friday. The business’s 50 day moving average price is $953.01 and its 200-day moving average price is $891.10. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The company has a market cap of $98.43 billion, a P/E ratio of 25.81, a P/E/G ratio of 2.58 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter in the previous year, the business earned $10.96 EPS. Regeneron Pharmaceuticals’s revenue was up .6% compared to the same quarter last year. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.59 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on REGN. Bank of America lifted their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. UBS Group lifted their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday. Barclays lifted their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. Finally, BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $976.41.

Insider Activity at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold a total of 13,729 shares of company stock worth $13,124,641 in the last quarter. 8.83% of the stock is owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.